Skip to main content
SpringerLink
Log in

Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis

  • Original Article
  • Published:
Irish Journal of Medical Science Aims and scope Submit manuscript

Abstract

Background

Tartrate-resistant acid phosphatase isoform 5b (TRACP5b) is a serum bone resorption marker. Our aim was to investigate its utility in monitoring metabolic bone disease.

Methods

Serum TRACP5b, C-terminal cross-linking telopeptide of type I collagen, urine N-terminal cross-linking telopeptide of type I collagen and free deoxypyridinoline were measured pre- and post-treatment with a parathyroid hormone analogue [PTH (1–34)] (n = 14) or a bisphosphonate (N-BP) (n = 8). TRACP5b, bone alkaline phosphatase (bone ALP), 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) were measured in 100 osteoporosis patients on prolonged bisphosphonate therapy.

Results

Changes in TRACP5b were smaller in magnitude but mimicked those of other bone resorption markers. Absolute changes in TRACP5b and the other resorption markers correlated significantly (p < 0.001). In patients on long-term bisphosphonates, TRACP5b and bone ALP levels were not suppressed. Vitamin D status was consistent with the level of supplementation.

Conclusion

TRACP5b has limited utility as a single marker of metabolic bone disease treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93(8):2948–2952. Doi:10.1210/jc.2007-2803

    Google Scholar 

  2. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22(5):346–350. doi:10.1097/BOT.0b013e318172841c

    Google Scholar 

  3. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267–2294. doi:10.1002/jbmr.253

    Article  PubMed  Google Scholar 

  4. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4):613–620. doi:10.1359/jbmr.2000.15.4.613

    Article  CAS  PubMed  Google Scholar 

  5. Diab T, Condon KW, Burr DB, Vashishth D (2006) Age-related change in the damage morphology of human cortical bone and its role in bone fragility. Bone 38(3):427–431. doi:10.1016/j.bone.2005.09.002

    Article  PubMed  Google Scholar 

  6. Szulc P, Delmas PD (2008) Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 19(12):1683–1704. doi:10.1007/s00198-008-0660-9

    Article  CAS  PubMed  Google Scholar 

  7. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2–S17

    Google Scholar 

  8. Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47(4):694–702

    CAS  PubMed  Google Scholar 

  9. Terreni A, Pezzati P (2012) Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab 9(2):80–84

    PubMed Central  PubMed  Google Scholar 

  10. Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA (2007) Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18(5):681–685. doi:10.1007/s00198-006-0286-8

    Article  CAS  PubMed  Google Scholar 

  11. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34(1):187–194. pii:S875632820300379X

    Google Scholar 

  12. Nanda KS, Ryan EJ, Murray BF, Brady JJ, McKenna MJ, Nolan N, O’Farrelly C, Hegarty JE (2009) Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol 7(8):894–899. doi:10.1016/j.cgh.2009.01.011

    Google Scholar 

  13. Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B, Dunne C, Hagan R, Duggan M, Jordan S, McKenna M, Hutchinson M, Tubridy N (2011) Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 82(3):317–322. doi:10.1136/jnnp.2010.220988

    Article  CAS  PubMed  Google Scholar 

  14. Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13(7):1124–1133. doi:10.1359/jbmr.1998.13.7.1124

    Article  CAS  PubMed  Google Scholar 

  15. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, Vuori I, Vaananen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20(10):1804–1812. doi:10.1359/JBMR.050403

    Article  CAS  PubMed  Google Scholar 

  16. Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45(6):1053–1058. doi:10.1016/j.bone.2009.07.091

    Google Scholar 

  17. Plotkin H, Gundberg C, Mitnick M, Stewart AF (1998) Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1–36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83(8):2786–2791

    CAS  PubMed  Google Scholar 

  18. Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40(6):1447–1452. doi:10.1016/j.bone.2006.09.008

    Google Scholar 

  19. Clarke B (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol 3(Suppl 3):S131–139. doi:10.2215/CJN.04151206

    Google Scholar 

  20. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30(6):886–890 pii:S8756328202007287

    Article  CAS  PubMed  Google Scholar 

  21. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Institute of Medicine (2011) Dietary reference intakes for calcium and vitamin D. The National Academies Press, USA

  22. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96(1):53–58. doi:10.1210/jc.2010-2704

    Article  CAS  PubMed  Google Scholar 

  23. McKenna MJ, Murray BF (2013) Vitamin D dose response is underestimated by Endocrine Society’s Clinical Practice Guideline. Endocrine Connections 2(2):87–95. doi:10.1530/ec-13-0008

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Metabolism Laboratory, St. Vincent’s University Hospital, Dublin, Ireland

    J. J. Brady, B. F. Murray, M. T. Kilbane, M. O’Keane & M. J. McKenna

  2. St. Michael’s Hospital, Dún Laoghaire, Dublin, Ireland

    R. K. Crowley & M. J. McKenna

  3. School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland

    M. J. McKenna

Authors
  1. J. J. Brady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. K. Crowley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. F. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. T. Kilbane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. O’Keane
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. J. McKenna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. J. Brady.

Additional information

J. J. Brady and R. K. Crowley are joint first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brady, J.J., Crowley, R.K., Murray, B.F. et al. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis. Ir J Med Sci 183, 47–52 (2014). https://doi.org/10.1007/s11845-013-0970-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-013-0970-6

Keywords

Search

Navigation